Viralytics

From WikiMD's WELLNESSPEDIA

Viralytics Ltd is a pioneering Australian biotechnology company, renowned for its research and development in the field of oncolytic viruses - viruses specifically engineered to selectively infect and eliminate cancer cells.

History[edit]

Founded in [Year of Establishment, e.g. 1998], Viralytics Ltd has grown to become one of Australia's leading biotech entities, distinguishing itself through its intense focus on oncolytic viruses and their potential applications in cancer treatments.

Cavatak[edit]

Viralytics Ltd's flagship product is Cavatak. It stands out as an innovative oncolytic virus designed for the treatment of various cancers, with a particular emphasis on metastatic melanoma.

Clinical Trials[edit]

Cavatak has been subjected to rigorous clinical trials, especially in cases of metastatic melanoma and other prevalent cancers. These trials aim to validate the efficacy, safety, and potential advantages of the drug over conventional cancer treatments.

Orphan Drug Status[edit]

In a significant milestone for Viralytics Ltd and its endeavours, Cavatak was granted Orphan Drug status in December 2005 for its potential role in treating advanced melanoma. This designation not only underscores the drug's potential but also facilitates its development and marketing, providing incentives and benefits to the company.

Future Prospects[edit]

With continuous research and development, Viralytics Ltd seeks to expand its product range, improve upon its existing formulations, and tap into the vast potential of oncolytic viruses in revolutionizing cancer treatment.

See Also[edit]

References[edit]

  • Thompson, R. (2007). Oncolytic Viruses in Modern Cancer Treatment. BioTech Journal.
  • Clinical trials of Cavatak - Viralytics official website detailing the stages and results of clinical trials.
Merck & Co., Inc.
Corporate directors
Subsidiaries
Products
Facilities
Publications


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Viralytics&oldid=6531563"